公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2018 | Aflibercept plus FOLFIRI in Asian patients with pretreated metastatic colorectal cancer: A randomized Phase III study | Li J.; Xu R.; Qin S.; Liu T.; Pan H.; Xu J.; Bi F.; Lim R.; Zhang S.; Ba Y.; Bai Y.; Fan N.; Tsuji A.; KUN-HUEI YEH ; Ma B.; Wei V.; Shi D.; Magherini E.; Shen L. | Future Oncology | 21 | 16 | |
2019 | CEO Hedging Opportunities and the Weighting of Performance Measures in Compensation Contracts | Hung S.; Pan H.; Wang T. | Contemporary Accounting Research | 2 | 1 | |
2021 | Cohort profile: Singapore Preconception Study of Long-Term Maternal and Child Outcomes (S-PRESTO) | Loo E.X.L.; Soh S.-E.; Loy S.L.; Ng S.; Tint M.T.; Chan S.-Y.; Huang J.Y.; Yap F.; Tan K.H.; Chern B.S.M.; Tan H.H.; Meaney M.J.; Karnani N.; Godfrey K.M.; Lee Y.S.; Chan J.K.Y.; Gluckman P.D.; Chong Y.-S.; Shek L.P.-C.; Eriksson J.G.; Chia A.; Fogel A.M.; Goh A.E.N.; Chu A.H.Y.; Rifkin-Graboi A.; Qiu A.; Lee B.W.; Cheon B.K.; Vaz C.; Henry C.J.; Forde C.G.; Chi C.; Koh D.X.P.; Phua D.Y.; Loh D.N.L.; Quah E.P.L.; Tham E.H.; Law E.C.N.; Magkos F.; Mueller-Riemenschneider F.; Yeo G.S.H.; Yong H.E.J.; Chen H.Y.; Pan H.; Bever H.P.S.; Tan H.M.; Aris I.B.M.; Tay J.; Xu J.; Yoong J.S.-Y.; Eriksson J.G.; Choo J.T.L.; Bernard J.Y.; Lai J.S.; Tan K.M.L.; Kwek K.Y.C.; McCrickerd K.; Narasimhan K.; Chong K.W.; Lee K.J.; Chen L.; Ling L.H.; LING-WEI CHEN ; Daniel L.M.; Fortier M.V.; Chong M.F.-F.; Chua M.C.; Leow M.K.-S.; Kee M.Z.L.; Gong M.; Michael N.; Lek N.; Teoh O.H.; Mishra P.; Li Q.L.J.; Velan S.S.; Ang S.B.; Cai S.; Goh S.H.; Lim S.B.; Tsotsi S.; Hsu S.C.-Y.; Toh S.-A.E.S.; Sadananthan S.A.; Tan T.H.; Yew T.W.; Gupta V.; Rajadurai V.S.; Han W.M.; Pang W.W.; Yuan W.L.; Zhu Y.; Cheung Y.B.; Chan Y.H.; Cheng Z.R.; the S-PRESTO Study Group | European Journal of Epidemiology | 29 | 29 | |
2009 | Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial | ANN-LII CHENG ; Kang Y.-K.; Chen Z.; Tsao C.-J.; Qin S.; Kim J.S.; Luo R.; Feng J.; Ye S.; Yang T.-S.; Xu J.; Sun Y.; Liang H.; Liu J.; Wang J.; Tak W.Y.; Pan H.; Burock K.; Zou J.; Voliotis D.; Guan Z. | The Lancet Oncology | 4852 | 4547 | |
2012 | Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: Subset analyses of the phase III Sorafenib Asia-Pacific trial | ANN-LII CHENG ; Guan Z.; Chen Z.; Tsao C.-J.; Qin S.; Kim J.S.; Yang T.-S.; Tak W.Y.; Pan H.; Yu S.; Xu J.; Fang F.; Zou J.; Lentini G.; Voliotis D.; Kang Y.-K. | European Journal of Cancer | 220 | 212 | |
2022 | Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial | Lu S.; Wang Q.; Zhang G.; Dong X.; Yang C.-T.; Song Y.; Chang G.-C.; Lu Y.; Pan H.; Chiu C.-H.; Wang Z.; Feng J.; Zhou J.; Xu X.; Guo R.; Chen J.; Yang H.; Chen Y.; Yu Z.; Shiah H.-S.; Wang C.-C.; Yang N.; Fang J.; Wang P.; Wang K.; Hu Y.; He J.; Wang Z.; Shi J.; Chen S.; Wu Q.; Sun C.; Li C.; Wei H.; Cheng Y.; Su W.-C.; Hsia T.-C.; Cui J.; Sun Y.; Ou S.-H.I.; Zhu V.W.; CHIH-HSIN YANG | Journal of Thoracic Oncology | 72 | 51 | |
2013 | Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): A randomised, double-blind trial | Wu Y.-L.; Lee J.S.; Thongprasert S.; CHONG-JEN YU ; Zhang L.; Ladrera G.; Srimuninnimit V.; Sriuranpong V.; Sandoval-Tan J.; Zhu Y.; Liao M.; Zhou C.; Pan H.; Lee V.; Chen Y.-M.; Sun Y.; Margono B.; Fuerte F.; Chang G.-C.; Seetalarom K.; Wang J.; Cheng A.; Syahruddin E.; Qian X.; Ho J.; Kurnianda J.; Liu H.E.; Jin K.; Truman M.; Bara I.; Mok T. | The Lancet Oncology | 277 | 247 | |
2005 | Ipr1 gene mediates innate immunity to tuberculosis | Pan H.; BO-SHIUN YAN ; Rojas M.; Shebzukhov Y.V.; Zhou H.; Kobzik L.; Higgins D.E.; Daly M.J.; Bloom B.R.; Kramnik I. | Nature | 381 | 349 | |
2015 | Linifanib versus sorafenib in patients with advanced hepatocellular carcinoma: Results of a randomized phase III trial | Cainap C.; Qin S.; Huang W.-T.; Chung I.J.; Pan H.; Cheng Y.; Kudo M.; Kang Y.-K.; PEI-JER CHEN ; Toh H.-C.; Gorbunova V.; Eskens F.A.L.M.; Qian J.; McKee M.D.; Ricker J.L.; Carlson D.M.; El-Nowiem S. | Journal of Clinical Oncology | 476 | 453 | |
2019 | A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma | Qin S.; Chan S.L.; Sukeepaisarnjaroen W.; Han G.; Choo S.P.; Sriuranpong V.; Pan H.; Yau T.; Guo Y.; Chen M.; Ren Z.; Xu J.; Yen C.-J.; ZHONG-ZHE LIN ; Manenti L.; Gu Y.; Sun Y.; Tiedt R.; Hao L.; Song W.; Tanwandee T. | Therapeutic Advances in Medical Oncology | 38 | 38 | |
2021 | Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression | Ryoo B.-Y.; ANN-LII CHENG ; Ren Z.; Kim T.-Y.; Pan H.; Rau K.-M.; Choi H.J.; Park J.-W.; Kim J.H.; Yen C.J.; Lim H.Y.; Zhou D.; Straub J.; Scheele J.; Berghoff K.; Qin S. | British Journal of Cancer | 20 | 17 | |
2016 | Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma | ANN-LII CHENG ; Thongprasert S.; Lim H.Y.; Sukeepaisarnjaroen W.; Yang T.-S.; Wu C.-C.; Chao Y.; Chan S.L.; Kudo M.; Ikeda M.; Kang Y.-K.; Pan H.; Numata K.; Han G.; Balsara B.; Zhang Y.; Rodriguez A.-M.; Zhang Y.; Wang Y.; Poon R.T.P. | Hepatology | 71 | 68 | |
2020 | Regorafenib in Chinese patients with metastatic colorectal cancer: Subgroup analysis of the phase 3 CONCUR trial | Xu J.; Xu R.-H.; Qin S.; Pan H.; Bai Y.; Chi Y.; Wang L.; Bi F.; Cheng Y.; Liu T.; Ma D.; Shen L.; Ba Y.; Liang J.; Wang X.; Yau T.C.C.; Ma B.B.; KUN-HUEI YEH ; Lin J.-K.; Kappeler C.; Shapiro J.; Kalmus J.; Li J. | Journal of Gastroenterology and Hepatology (Australia) | 7 | 5 | |
2015 | Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): A randomised, double-blind, placebo-controlled, phase 3 trial | Li J.; Qin S.; Xu R.; Yau T.C.C.; Ma B.; Pan H.; Xu J.; Bai Y.; Chi Y.; Wang L.; KUN-HUEI YEH ; Bi F.; Cheng Y.; Le A.T.; Lin J.-K.; Liu T.; Ma D.; Kappeler C.; Kalmus J.; Kim T.W. | The Lancet Oncology | 597 | 536 | |
2020 | Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial | CHIH-HSIN YANG ; Camidge D.R.; Yang C.-T.; Zhou J.; Guo R.; Chiu C.-H.; Chang G.-C.; Shiah H.-S.; Chen Y.; Wang C.-C.; Berz D.; Su W.-C.; Yang N.; Wang Z.; Fang J.; Chen J.; Nikolinakos P.; Lu Y.; Pan H.; Maniam A.; Bazhenova L.; Shirai K.; Jahanzeb M.; Willis M.; Masood N.; Chowhan N.; Hsia T.-C.; Jian H.; Lu S. | Journal of Thoracic Oncology | 87 | 75 | |
2020 | Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial | Wu Y.-L.; Cheng Y.; Zhou J.; Lu S.; Zhang Y.; Zhao J.; Kim D.-W.; Soo R.A.; Kim S.-W.; Pan H.; Chen Y.-M.; Chian C.-F.; Liu X.; Tan D.S.W.; Bruns R.; Straub J.; Johne A.; Scheele J.; Park K.; CHIH-HSIN YANG ; Liu Z.; Chen X.; Wang M.; Yu S.; Zhang H.; Fang J.; Li W.; Yang C.-H.; Chang G.-C.; Hsia T.-C.; Yang C.-T.; Wang C.-C.; Cho B.C.; Lee K.H.; Kim Y.-C.; An H.J.; Woo I.S.; Cho J.Y.; Shin S.W.; Lee J.-S.; Kim J.-H.; Yoo S.S.; Kato T.; Shinagawa N.; Tan S.W.D.; Ngo L.S.-M.; Ratnavelu K.; Ahmad A.R.; Liam C.K.; de Marinis F.; Tassone P.; Molla A.I.; Calles Blanco A.; Lazaro Quintela M.E.; Felip Font E.; Dingemans A.-M.; Bui L. | The Lancet Respiratory Medicine | 161 | 128 | |